Reza Fathi
Chief Tech/Sci/R&D Officer presso REDHILL BIOPHARMA LTD.
Patrimonio netto: 37 524 $ in data 31/03/2024
Profilo
Reza Fathi is a Senior Vice President-Research & Development at RedHill Biopharma Ltd.
He previously worked as a Director-Research Operations at XTL Biopharmaceuticals Ltd., Director-Research & Operations at VivoQuest, Inc., Head-Discovery Group at PharmaGenics, Inc., and Manager-Chemical Biology Research at Harvard Medical School.
Dr. Fathi holds a doctorate degree from Rutgers State University of New Jersey and an undergraduate degree from Texas Tech University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
REDHILL BIOPHARMA LTD.
0.01% | 21/04/2023 | 708 000 ( 0.01% ) | 37 524 $ | 31/03/2024 |
Posizioni attive di Reza Fathi
| Società | Posizione | Inizio |
|---|---|---|
| REDHILL BIOPHARMA LTD. | Chief Tech/Sci/R&D Officer | 01/05/2010 |
Precedenti posizioni note di Reza Fathi
| Società | Posizione | Fine |
|---|---|---|
| XTL BIOPHARMACEUTICALS LTD. | Chief Tech/Sci/R&D Officer | - |
VivoQuest, Inc.
 VivoQuest, Inc. BiotechnologyHealth Technology VivoQuest, Inc. is engaged into the discovery and development of prescription drugs based on natural compounds derived small molecules. The in-house discovery research program in chemistry and biology aims at establishing and screening unique libraries of natural product-like compounds. VivoQuest's initial therapeutic area is the anti-viral field, including HIV and hepatitis C. VivoQuest is headquartered in Valley Cottage, NY. | Chief Operating Officer | - |
| Harvard Medical School | Corporate Officer/Principal | 01/01/2000 |
PharmaGenics, Inc.
 PharmaGenics, Inc. Miscellaneous Commercial ServicesCommercial Services PharmaGenics, Inc. develops therapeutic products for cancer. The American company was founded by Mike I. Sherman. PharmaGenics was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on June 18, 1997 for $112 million. | Corporate Officer/Principal | 01/01/1998 |
Formazione di Reza Fathi
| Rutgers State University of New Jersey | Doctorate Degree |
| Texas Tech University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| XTL BIOPHARMACEUTICALS LTD. | Health Technology |
| REDHILL BIOPHARMA LTD. | Health Technology |
| Aziende private | 2 |
|---|---|
PharmaGenics, Inc.
PharmaGenics, Inc. Miscellaneous Commercial ServicesCommercial Services PharmaGenics, Inc. develops therapeutic products for cancer. The American company was founded by Mike I. Sherman. PharmaGenics was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on June 18, 1997 for $112 million. | Commercial Services |
VivoQuest, Inc.
VivoQuest, Inc. BiotechnologyHealth Technology VivoQuest, Inc. is engaged into the discovery and development of prescription drugs based on natural compounds derived small molecules. The in-house discovery research program in chemistry and biology aims at establishing and screening unique libraries of natural product-like compounds. VivoQuest's initial therapeutic area is the anti-viral field, including HIV and hepatitis C. VivoQuest is headquartered in Valley Cottage, NY. | Health Technology |
- Borsa valori
- Insiders
- Reza Fathi
